EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis

Fanchao Zhou, Guoming Li, Ruixiang Tan, Guodong Wu, Changsheng Deng

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70086 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, 2025. Written by Fanchao Zhou and 4 co-authors. Institution: Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China. Major MEDLINE topics: Artemisinins, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Autoimmune Diseases. Cited 11 times so far (Crossref); 166 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) result from immune self‐tolerance loss, causing tissue damage. Standard treatments targeting late‐stage inflammation often have serious side effects. Artemisinin, known for its antimalarial properties, shows potential immunomodulatory effects. This review examines artemisinin's application in SLE and RA, emphasizing its therapeutic potential and mechanism insights. From 2014 to 2024, we searched PubMed, Web of Science, and Google Scholar using keywords ‘artemisinins’, ‘SLE’, and ‘RA’. Artemisinins modulate immune pathways (PI3K/Akt, HIF‐1α/NF‐κB, Nrf2/HO‐1, p62/Nrf2), balance Th17/Treg cells and M1/M2 macrophages, inhibit ROS production, and suppress B‐cells, fibroblast‐like synoviocytes, and osteoclasts, affecting SLE/RA progression. Structure–activity relationship analysis indicates that the effects of artemisinin are mainly due to their endoperoxide bridge and sesquiterpene lactone structures. This review highlights artemisinin's potential for treating various autoimmune diseases and aiding drug development.

Subjects

MeSH terms (MEDLINE)

ArtemisininsLupus Erythematosus, SystemicArthritis, RheumatoidAutoimmune DiseasesHumansAnimals

Author keywords

DHARASLESM934artemisininartesunate

Substances

Artemisinins

Authors and institutions

  • Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Nanchang Health Vocational And Technical College, Nanchang, China.

Funding

  • National Natural Science Foundation of China

Cite

APA

Zhou, F., Li, G., Tan, R., Wu, G., & Deng, C. (2025). Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis. British Journal of Pharmacology. https://doi.org/10.1111/bph.70086

Vancouver

Zhou F, Li G, Tan R, Wu G, Deng C. Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis. British Journal of Pharmacology. 2025. doi:10.1111/bph.70086

BibTeX
@article{Zhou2025,
  author = {Zhou, Fanchao and Li, Guoming and Tan, Ruixiang and Wu, Guodong and Deng, Changsheng},
  title = {Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70086}
}
Start for free →